3SBIO (01530) announced its full-year results for the period ending December 31, 2025. The Group's revenue increased by 94.3% to RMB 17.696 billion. Gross profit rose by 108.8% to RMB 16.347 billion, with a gross profit margin of 92.4%. Profit attributable to owners of the parent company surged by 305.8% to RMB 8.482 billion. A final dividend of 25 HK cents per share was declared.

3SBIO is a leading biotechnology company in Mainland China. As a pioneer in China's biotech sector, the Group possesses extensive experience in the research, development, production, and marketing of biopharmaceutical products. Its core commercial products include several biologics, such as TPIAO, the recombinant human erythropoietin (rhEPO) products YIBAIO and CIPHER, YISAIPU and CYRAMZA, as well as the minoxidil drug series from its small molecule product pipeline, MINIDI.

TPIAO is currently the world's only commercialized recombinant human thrombopoietin (rhTPO) product. According to IQVIA, in 2025, TPIAO held a 60.4% share of the thrombocytopenia treatment market in Mainland China by sales value. With its two rhEPO products, the Group has been the leader in the Mainland China rhEPO market for over two decades, collectively capturing 39.6% of the total market share in 2025. YISAIPU was the first tumor necrosis factor (TNF) α inhibitor product launched in the Mainland China market. MINIDI also holds a dominant position in the hair loss treatment drug market in Mainland China. The Group is further expanding its therapeutic areas by increasing its product portfolio through internal R&D efforts and various external strategic collaborations.